• Explore /
  • Poster
  • / Phase II study of lower-dose pracinostat plus azacitidine safety and efficacy in patients with high/very high-risk myelodysplastic syndromes.

Phase II study of lower-dose pracinostat plus azacitidine safety and efficacy in patients with high/very high-risk myelodysplastic syndromes.

Abstract Poster

Authors

null

Ehab L. Atallah

Hematologic Malignancies, Medical College of Wisconsin, Milwaukee, WI

Ehab L. Atallah , Samer K. Khaled , Brenda W. Cooper , Erica D. Warlick , David A. Ramies , Joanne Li , Riccardo Spezia , Silvia Mappa , Michael Kenneth Keng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Myelodysplastic Syndromes (MDS)

Clinical Trial Registration Number

NCT03151304

Citation

J Clin Oncol 38: 2020 (suppl; abstr 7556)

DOI

10.1200/JCO.2020.38.15_suppl.7556

Abstract #

7556

Poster Bd #

329

Abstract Disclosures

Similar Posters

First Author: Jacqueline Suen Garcia

First Author: Chun Yew Fong

First Author: Rachael A Safyan

First Author: Miao Wang